tiprankstipranks
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
US Market

Allogene Therapeutics (ALLO) Ownership - Who Owns Allogene Therapeutics?

Compare
1,396 Followers

Allogene Therapeutics (ALLO) Ownership Overview

10.87%23.03%38.86%10.04%17.19%
10.87% Insiders
38.86% Other Institutional Investors
10.04% ETFs
17.19% Public Companies and
Individual Investors
The ownership structure of Allogene Therapeutics (ALLO) stock is a mix of institutional, retail, and individual investors. Approximately 71.93% of the company’s stock is owned by Institutional Investors, 10.87% is owned by Insiders, and 17.19% is owned by Public Companies and Individual Investors.
The ownership structure of Allogene Therapeutics (ALLO) stock is a mix of institutional, retail, and individual investors. Approximately 61.89% of the company’s stock is owned by Institutional Investors, 10.87% is owned by Insiders, and 10.04% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Dec 10, 2024
xxxxxxxxxxxxx
$19916
Dec 09, 2024
Franz Humer
Director
xxxxxxxxxxxxx
$19917
Jun 03, 2024
Franz Humer
Director
xxxxxxxxxxxxx
$26096
May 20, 2024
xxxxxxxxxxxxx
$4999997

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Dec 31, 2024
xxxxxxxxxxxxx
$88899
Dec 31, 2024
xxxxxxxxxxxxx
$439589
Dec 31, 2024
xxxxxxxxxxxxx
$9287294
Dec 31, 2024
xxxxxxxxxxxxx
$10495234

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
11,009,103Insider5.07%21,357,660
8,230,433Insider3.79%15,967,040
7,573,089Institution3.49%14,691,793
6,896,552Institution3.17%13,379,311
6,709,877Institution3.09%13,017,161
6,496,090Institution2.99%12,602,415
6,437,102Institution2.96%12,487,978
5,074,832Institution2.34%9,845,174
4,927,340Institution2.27%9,559,040
4,473,549Institution2.06%8,678,685

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
6,896,552Institution3.17%13,379,311
6,709,877Institution3.09%13,017,161
6,437,102Institution2.96%12,487,978
5,074,832Institution2.34%9,845,174
4,473,549Institution2.06%8,678,685
3,169,230Institution1.46%6,148,306
2,969,370Institution1.37%5,760,578
2,204,834Institution1.01%4,277,378
1,835,770Institution0.84%3,561,394
1,808,122Institution0.83%3,507,757

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
4,278,056Institution1.97%8,342,209
3,838,387Institution1.77%7,254,551
3,442,500Institution1.58%6,678,450
2,214,297Institution1.02%4,317,879
1,160,965Institution0.53%2,252,272
875,091Institution0.40%1,697,677
707,612Institution0.33%1,337,387
584,129Institution0.27%1,139,052
464,771Institution0.21%906,303
457,473Institution0.21%864,624

FAQ

Who Owns Allogene Therapeutics Inc (ALLO)?
According to the latest TipRanks data, approximately 38.86% of the company's stock is held by institutional investors, 10.87% is held by insiders, and 17.19% is held by retail investors.
    What percentage of Allogene Therapeutics Inc (ALLO) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 38.86% of Allogene Therapeutics Inc (ALLO) stock is held by institutional investors.
      What percentage of Allogene Therapeutics Inc (ALLO) stock is held by retail investors?
      According to the latest TipRanks data, approximately 17.19% of Allogene Therapeutics Inc (ALLO) stock is held by retail investors.
        Who owns the most shares of Allogene Therapeutics Inc (ALLO)?
        Arie Belldegrun owns the most shares of Allogene Therapeutics Inc (ALLO).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis